Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
>
Chemicals & Drugs
>
Immunologic Factor
>
CA-125 Antigen
CA-125 Antigen
CA-125 Antigen is a tumor marker that can be used to monitor the progression and treatment of certain types of cancer, particularly ovarian cancer.
It is a glycoprotein that is elevated in the blood of individuals with these conditions.
Researchers can leverage PubCompare.ai's AI-driven platform to easily locate and compare protocols from scientific literature, pre-prints, and patents related to CA-125 Antigen, ensuring reproducibility and accuracy in their work.
Experiance the power of PubCompare.ai today to identify the best protocols and products for your CA-125 Antigen research projects.
It is a glycoprotein that is elevated in the blood of individuals with these conditions.
Researchers can leverage PubCompare.ai's AI-driven platform to easily locate and compare protocols from scientific literature, pre-prints, and patents related to CA-125 Antigen, ensuring reproducibility and accuracy in their work.
Experiance the power of PubCompare.ai today to identify the best protocols and products for your CA-125 Antigen research projects.
Most cited protocols related to «CA-125 Antigen»
Biological Assay
Biological Markers
BLOOD
CA-125 Antigen
Cyst
Diagnosis
Ethics Committees, Research
Female Castrations
Freezing
Operative Surgical Procedures
Ovarian Cysts
Ovariectomy
Pathologists
Patients
Pelvis
Physicians
Plasma
Serum
Specimen Collection
Tissues
Ultrasonography
Urine
Woman
The UKCTOCS is a randomised controlled trial aiming to assess the impact of screening on mortality from ovarian cancer while comprehensively evaluating performance characteristics of the screening strategies, physical and psychological morbidity, compliance, and cost. The design involves 200 000 women randomised to annual screening with serum CA 125 or transvaginal ultrasound or no intervention (fig 1). The inclusion criteria were women aged 50-74 and with postmenopausal status; the exclusion criteria were bilateral oophorectomy, previous ovarian malignancy, increased risk of familial ovarian cancer, active non-ovarian malignancy, and participation in other ovarian cancer screening trials.
A senior investigator leads trial management based at the coordinating centre. We use a custom built, web based trial management system to centralise and automate trial processes. We identified NHS trusts (trial centres) wishing to participate and set them up in a staggered fashion over the course of two years. Recruitment started at a trial centre when at least 1500 local women had accepted the invitation. The launch of the trial was accompanied by national media coverage. This was followed by local media coverage in the form of radio interviews and newspaper articles as each centre started recruitment. We briefed the staff manning the telephone lines of the patient support charities OVACOME and Cancer BACUP and provided them with answers to frequently asked questions before any publicity.
A senior investigator leads trial management based at the coordinating centre. We use a custom built, web based trial management system to centralise and automate trial processes. We identified NHS trusts (trial centres) wishing to participate and set them up in a staggered fashion over the course of two years. Recruitment started at a trial centre when at least 1500 local women had accepted the invitation. The launch of the trial was accompanied by national media coverage. This was followed by local media coverage in the form of radio interviews and newspaper articles as each centre started recruitment. We briefed the staff manning the telephone lines of the patient support charities OVACOME and Cancer BACUP and provided them with answers to frequently asked questions before any publicity.
Full text: Click here
CA-125 Antigen
Female Castrations
Malignant Neoplasms
Ovarian Cancer
Patients
Physical Examination
Serum
Ultrasonics
Woman
Aftercare
Biological Assay
CA-125 Antigen
Disease Progression
Drug Tapering
Eligibility Determination
Genome
Germ-Line Mutation
Homologous Recombination
Malignant Neoplasms
Mutation
Neoplasms
Ovary
Patients
Placebos
Radionuclide Imaging
rucaparib
Sodium Chloride
Symptom Assessment
Tissues
X-Ray Computed Tomography
X-Rays, Diagnostic
Bevacizumab
CA-125 Antigen
Cancer of the Fallopian Tube
Central Nervous System
Conferences
Dietary Fiber
Disease Progression
Endometrium
Ethics Committees, Research
Inpatient
Malignant Neoplasms
Neoplasm Metastasis
Neoplasms
Ovary
Patients
Peritoneum
Pharmacotherapy
Placebos
Platinum
Poly(ADP-ribose) Polymerase Inhibitors
Residual Cancer
Residual Tumor
Serum
Treatment Protocols
X-Rays, Diagnostic
The volume of ascites varied between patients. CN patients had lower ascites volumes (100 ml−2L), compared to CR patients (100 ml−17 L). However, in order to standardise the experimental protocol only 500 ml of ascites was used to collect cells. Contaminating red blood cells in the cell pellet of ascites were removed by hypotonic lysis in sterile MilliQ H2O. The bulk of ascites cells were seeded on low attachment plates (Corning Incorporated, NY) in MCDB:DMEM (50∶50) growth medium supplemented with fetal bovine serum (10%), glutamine (2 mM) and penicillin/streptomycin (2 mM) (Life Technologies, CA, USA). Cells were maintained at 37°C in the presence of 5% CO2. Under these conditions, NAD cells floated as spheroids in the medium while AD cells attached to low attachment plates. After 2–3 days, floating NAD spheroids (dispersed by pipetting) and AD cells were screened for CA125, EpCAM, cyt 7 and FSP by flow cytometry. AD cells were maintained in plastic tissue culture flasks while NAD spheroids were maintained on low attachment plates. Cells were passaged weekly and experiments were performed within 1–2 passages.
Full text: Click here
Ascites
CA-125 Antigen
Cells
Dietary Fiber
Erythrocytes
Fetal Bovine Serum
Flow Cytometry
Glutamine
Patients
Penicillins
Sterility, Reproductive
Streptomycin
TACSTD1 protein, human
Tissues
Most recents protocols related to «CA-125 Antigen»
Example 3
Human T cells are infected with the pseudotyped CD28-CA125-PD1 VSV-G virus. 24 hrs to 48 hrs post viral infection, the T cell culture medium is collected and checked for the presence of proinflammatory cytokines. These results will show that T cells are activated by CD28-CA125-PD1 VSV-G, as evidenced by presence of proinflammatory cytokines such as IFN-β and IL-2 in the cell culture supernatant of CD28-CA125-PD1 VSV-G infected human T cells.
EphA2-overexpressing gastric cancer cells, from KATO3 cell line, are infected with pseudotyped CD28-CA125-PD1 VSV-G or non-pseudotyped CD28-CA125-PD1 VSV virus and the cell proliferation is assessed. These results will show that cell proliferation is significantly reduced in cells KATO3 cells infected with pseudotyped CD28-CA125-PD1 VSV-G compared to KATO3 cells infected with non-pseudotyped CD28-CA125-PD1 VSV virus.
Full text: Click here
CA-125 Antigen
Cell Lines
Cell Proliferation
Cells
Culture Media
Cytokine
Gastric Cancer
Gastrin-Secreting Cells
Homo sapiens
Neoplasms
T-Lymphocyte
Thomsen-Friedenreich antibodies
Virus
Virus Diseases
This study (clinical-trial ID: NCT05313854-clinicaltrials.gov) was approved by the Ethical Committee of Renji Hospital, Shanghai Jiao Tong University. A total of 78 PDAC from 2014 to 2020 were enrolled in this study. The inclusion criteria were: 1) histologically confirmed PDAC; 2) with complete contrast-enhanced MRI data; 3) with complete TNM staging information and tumor markers data (CA199, CEA and CA125). The exclusion criteria were: 1) malignancy other than PDAC; 2) with missing survival information.
Full text: Click here
Anophthalmia with pulmonary hypoplasia
CA-125 Antigen
Malignant Neoplasms
Tumor Markers
Treatment in experimental arm is based on molecular classification. Participants with POLEmut subtype, accounting for approximately 10% of all EEC and having quite a good prognosis [1 (link)], will be observed. An estimated 70% of patients with the MMRd or NSMP subtype will receive VBT (either 3 fractions of 7 Gy to 5 mm depth or 5 fractions of 6 Gy to the surface). Approximately 20% will have a p53abn profile and receive combined chemotherapy and radiotherapy (CTRT), with 4 adjuvant cycles of carboplatin and paclitaxel, followed by external beam pelvic radiotherapy (EBRT, 45–50 Gy) (Fig. 1 ).
The preferred treatment for the standard arm is recommended in accordance with the NCCN guidelines version 1 (2022) according to the clinicopathological risk factors [4 ]. Patients with IR (stage IA grade 3 or stage IB grade 1–2) will receive adjuvant VBT (3 fractions of 7 Gy or 5 fractions of 6 Gy). Patients with HIR (stage IB grade 3 or stage II) will receive adjuvant EBRT and/or VBT. The suggested dose for EBRT is 45-50 Gy in daily fractions of 1.8 Gy over 25–28 fractions, 5 times a week. The total dose for EBRT and VBT is 65 Gy.
Patients will be clinically evaluated during alternating follow-up visits with their gynecologist and radiation oncologist every 3 months for the first year, every 6 months for the next two years, and each year for the 4th and 5th years. Pelvic examination and serum CA125 test will be done at each visit. CT scan of abdomen, pelvis and chest will be done every six months. A comprehensive assessment will be performed when recurrence or metastasis is suspected, and treatment with curative intention will be initiated when necessary.
The preferred treatment for the standard arm is recommended in accordance with the NCCN guidelines version 1 (2022) according to the clinicopathological risk factors [4 ]. Patients with IR (stage IA grade 3 or stage IB grade 1–2) will receive adjuvant VBT (3 fractions of 7 Gy or 5 fractions of 6 Gy). Patients with HIR (stage IB grade 3 or stage II) will receive adjuvant EBRT and/or VBT. The suggested dose for EBRT is 45-50 Gy in daily fractions of 1.8 Gy over 25–28 fractions, 5 times a week. The total dose for EBRT and VBT is 65 Gy.
Patients will be clinically evaluated during alternating follow-up visits with their gynecologist and radiation oncologist every 3 months for the first year, every 6 months for the next two years, and each year for the 4th and 5th years. Pelvic examination and serum CA125 test will be done at each visit. CT scan of abdomen, pelvis and chest will be done every six months. A comprehensive assessment will be performed when recurrence or metastasis is suspected, and treatment with curative intention will be initiated when necessary.
Abdomen
Antineoplastic Combined Chemotherapy Protocols
CA-125 Antigen
Carboplatin
Chest
Gynecologist
Neoplasm Metastasis
Paclitaxel
Patients
Pelvic Examination
Pelvis
Pharmaceutical Adjuvants
Prognosis
Radiation Oncologists
Radiotherapy
Recurrence
Serum
Therapies, Investigational
X-Ray Computed Tomography
Demographic variables collected for the study included age, sex, smoking status, and medical history. Basic clinical variables included tumor stage, site, size, pathological type, and genotype (Table 1 ). A total of 46 laboratory test index variables were included in the study, including: white blood cell count (WBC), red blood cell count (RBC), platelet (PLT), hemoglobin (Hb), neutrophil count (NEUT), lymphocyte count (LYM), monocyte count (MONO), eosinophil count (EOS), basophil count (BASO), prothrombin time (PT), activate part plasma prothrombin time (APTT), fibrinogen (FIB), D-dimer, international normalized ratio (INR), arterial oxygen partial pressure (PaO), arterial blood carbon dioxide partial pressure (PaCO2), arterial oxygen saturation (SaO), pH, base excess (BE), standard bicarbonate (SB), uric acid (UA), α-hydroxybutyrate dehydrogenase (α-HBDH), total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL), creatinine (Cr), blood urea nitrogen (BUN), blood sugar (GLU), serum potassium ion (K), sodium ion (Na), serum chlorine (CL), serum calcium (Ca), carbon dioxide combining power (CO2CP), aspartate aminotransferase (AST), serum creatine kinase (CK), serum creatine kinase isoenzyme (CK-MB), lactate dehydrogenase (LDH), alpha-L-fucosidase (AFU), carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), neuron specific enolase (NSE), carbohydrate antigen 125 (CA125), carbohydrate antigen 153 (CA153), and systolic and diastolic blood pressure.
Activated Partial Thromboplastin Time
alpha-hydroxybutyrate dehydrogenase
antigen CYFRA21.1
Antigens
Arteries
Basophils
Bicarbonates
BLOOD
Blood Glucose
Blood Platelets
CA-125 Antigen
Calcium, Dietary
Carbohydrates
Carbon dioxide
Carcinoembryonic Antigen
Chlorine
Cholesterol
Cholesterol, beta-Lipoprotein
Creatine Kinase
Creatinine
Eosinophil
Erythrocyte Count
fibrin fragment D
Fibrinogen
Fucosidase
gamma-Enolase
Genotype
Hemoglobin
High Density Lipoprotein Cholesterol
International Normalized Ratio
Isoenzyme CPK MB
Isoenzymes
Lactate Dehydrogenase
Leukocyte Count
Lymphocyte Count
Monocytes
Neoplasms
Neutralization Tests
Neutrophil
Oxygen
Oxygen Saturation
Partial Pressure
Plasma
Potassium
Pressure, Diastolic
Serum
Sodium
Systole
Times, Prothrombin
Transaminase, Serum Glutamic-Oxaloacetic
Triglycerides
Urea Nitrogen, Blood
Uric Acid
Clinical data, including patient age, CA125 (within 2 weeks before surgery), HE4 (within 2 weeks before surgery), and tumor grade by preoperative D&C, were obtained through the hospital information management system. Pathological reports should include tumor differentiation, depth of MI, CSI, and FIGO stage.
Two radiologists (A and B with 5 and 12 years of experience, respectively) reviewed the MRI images of each patient, blinded to the pathological and clinical data. The evaluation items included maximum tumor diameter (mean value of the tumor on axial T2WI, DWI, and DCE-T1WI), depth of MI, CSI, and LNM. Disagreements were re-evaluated by another senior physician.
Two radiologists (A and B with 5 and 12 years of experience, respectively) reviewed the MRI images of each patient, blinded to the pathological and clinical data. The evaluation items included maximum tumor diameter (mean value of the tumor on axial T2WI, DWI, and DCE-T1WI), depth of MI, CSI, and LNM. Disagreements were re-evaluated by another senior physician.
Full text: Click here
CA-125 Antigen
Neoplasms
Operative Surgical Procedures
Patients
Physicians
Radiologist
Top products related to «CA-125 Antigen»
Sourced in United States, Germany, United Kingdom, China, Italy, Japan, France, Sao Tome and Principe, Canada, Macao, Spain, Switzerland, Australia, India, Israel, Belgium, Poland, Sweden, Denmark, Ireland, Hungary, Netherlands, Czechia, Brazil, Austria, Singapore, Portugal, Panama, Chile, Senegal, Morocco, Slovenia, New Zealand, Finland, Thailand, Uruguay, Argentina, Saudi Arabia, Romania, Greece, Mexico
Bovine serum albumin (BSA) is a common laboratory reagent derived from bovine blood plasma. It is a protein that serves as a stabilizer and blocking agent in various biochemical and immunological applications. BSA is widely used to maintain the activity and solubility of enzymes, proteins, and other biomolecules in experimental settings.
Sourced in Germany, Switzerland, United States, China, Sweden, United Kingdom, Japan, Canada
The Cobas e601 is an automated immunochemistry analyzer used for in vitro diagnostic testing. It is designed to perform a wide range of immunoassay tests, including those for hormones, tumor markers, and infectious diseases. The Cobas e601 utilizes electrochemiluminescence technology to provide accurate and reliable results.
Sourced in Germany, Switzerland, United States, Italy, Japan, China, Denmark
The Cobas e602 is an automated electrochemiluminescence immunoassay (ECLIA) analyzer produced by Roche. It is designed for the in vitro quantitative determination of analytes in human samples. The Cobas e602 provides high-throughput testing and is suitable for clinical laboratory applications.
Sourced in Germany, Switzerland, United States, Japan, United Kingdom, Denmark, France, Poland
The Cobas e411 is a compact and fully automated immunoassay analyzer designed for clinical laboratory settings. It is capable of performing a wide range of immunoassay tests, including those for hormones, therapeutic drug monitoring, and infectious disease markers. The Cobas e411 is known for its reliability, ease of use, and efficient throughput.
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in Germany
The ARCHITECT CA 125 II assay is a laboratory equipment product designed to measure the levels of the CA 125 protein in patient samples. CA 125 is a biomarker commonly used in the monitoring and management of ovarian cancer. The assay utilizes immunoassay technology to quantify the CA 125 levels in the sample.
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
Sourced in United States, Austria, Japan, Belgium, New Zealand, United Kingdom, France
R is a free, open-source software environment for statistical computing and graphics. It provides a wide variety of statistical and graphical techniques, including linear and nonlinear modeling, classical statistical tests, time-series analysis, classification, clustering, and others.
Sourced in Switzerland, Germany, United States, Japan, Denmark, Italy, France, United Kingdom, Belgium, Norway, China, Israel, Poland, Netherlands, Sweden
The Cobas 6000 is an automated clinical chemistry and immunoassay analyzer system designed for high-volume laboratory testing. It combines the features of two separate instruments, the Cobas c 501 module for clinical chemistry and the Cobas e 601 module for immunoassays, into a single integrated platform. The Cobas 6000 system is capable of performing a wide range of diagnostic tests, including biochemical, immunological, and specialty assays.
More about "CA-125 Antigen"
CA-125, also known as cancer antigen 125, is a well-established tumor marker that plays a crucial role in monitoring the progression and treatment of certain types of cancer, particularly ovarian cancer.
This glycoprotein is elevated in the blood of individuals with these conditions, making it a valuable diagnostic and prognostic tool.
Researchers can leverage the power of PubCompare.ai's AI-driven platform to easily locate and compare protocols from scientific literature, preprints, and patents related to CA-125.
This ensures reproducibility and accuracy in their work, as they can identify the best protocols and products for their CA-125 research projects.
In addition to CA-125, there are several other related terms and concepts that are relevant to this field of study.
Bovine serum albumin (BSA) is a commonly used protein in various biological assays, including those involving CA-125.
The Cobas e601, Cobas e602, and Cobas e411 are automated immunoassay analyzers that can be used to measure CA-125 levels, while the ARCHITECT CA 125 II assay is a specific test for detecting and quantifying CA-125.
Fetal bovine serum (FBS) is another important component in cell culture media, and it may be used in experiments related to CA-125.
Statistical software like SAS version 9.4 and R software can be utilized for data analysis and interpretation in CA-125 research.
By leveraging the insights and tools provided by PubCompare.ai, researchers can optimize their CA-125 Antigen research, ensuring that they have access to the most reliable and up-to-date protocols and products.
Experiance the power of PubCompare.ai today to take your CA-125 Antigen research to new heights.
This glycoprotein is elevated in the blood of individuals with these conditions, making it a valuable diagnostic and prognostic tool.
Researchers can leverage the power of PubCompare.ai's AI-driven platform to easily locate and compare protocols from scientific literature, preprints, and patents related to CA-125.
This ensures reproducibility and accuracy in their work, as they can identify the best protocols and products for their CA-125 research projects.
In addition to CA-125, there are several other related terms and concepts that are relevant to this field of study.
Bovine serum albumin (BSA) is a commonly used protein in various biological assays, including those involving CA-125.
The Cobas e601, Cobas e602, and Cobas e411 are automated immunoassay analyzers that can be used to measure CA-125 levels, while the ARCHITECT CA 125 II assay is a specific test for detecting and quantifying CA-125.
Fetal bovine serum (FBS) is another important component in cell culture media, and it may be used in experiments related to CA-125.
Statistical software like SAS version 9.4 and R software can be utilized for data analysis and interpretation in CA-125 research.
By leveraging the insights and tools provided by PubCompare.ai, researchers can optimize their CA-125 Antigen research, ensuring that they have access to the most reliable and up-to-date protocols and products.
Experiance the power of PubCompare.ai today to take your CA-125 Antigen research to new heights.